SABS

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

• SAB Biotherapeutics (SABS) Received FDA Fast Track Designation for SAB-142 in Newly Diagnosed Stage 3 Type 1 Diabetes.Oct 14, 2026

News

• Breakthrough T1D awarded a grant supporting the PRISE hATG study of SAB 142 in stage 3 type 1 diabetesJul 8, 2026
• SAB BIO presented additional clinical and mechanistic Phase 1 data for SAB-142 in autoimmune type 1 diabetesApr 22, 2026
• SAB BIO reported additional Phase 1 data for SAB-142 in adults with established autoimmune type 1 diabetesMar 10, 2026
• First patient dosed in SAB BIO's SAFEGUARD trial of SAB-142 for Stage 3 T1DDec 18, 2025
• SAB BIO announces positive confirmatory Phase 1 results for SAB-142 in Stage 3 T1DDec 17, 2025